Statistical Analysis LM02 & LM04

28 March 2025

Kirollos Roufail

Today...


- 1. Improvement in Vessels Reconstruction
- 2. Statistical Analysis
 - Statistical Tests Flowchart
 - Analysis run on real segmented vessels data
 - Random Sampling attempt
 - Notebook
- 3. Carcinogenic Angiogenesis Parameters

Overview of Statistical Analysis


Objective: Comparison of treatments across two models (LM02 and LM04).

Methods Used:

- 1. Descriptive Statistics
- 2. Normality Assessment: Shapiro-Wilk Test & Anderson-Darling Test
- 3. Kruskal-Wallis Test
- 4. Dunn's Post-hoc Test
- 5. Effect Size Analysis (Cliff's Delta)



LM02



Descriptive Statistics - LM02

Treatment	Sample Size (n)	Mean	SD	Median	IQR
CTR	3353	79.3	29.2	71.4	20.7
DTX	7101	88.5	57.2	71.9	29.8
ED1	7505	80.3	44.6	67.1	23.9
ED2	18149	93.4	56.5	76.2	35.3

Normality Assessment - LM02

Tests Used: Shapiro-Wilk and Anderson-Darling

Results:

- CTR: p-value = 1.531 x 10⁻⁶¹ (Non-normal distribution)
- DTX, ED1, ED2: p-value = 3.7 x 10⁻²⁴ (Non-normal distribution)

Kruskal-Wallis Test Results - LM02

Test Statistic: Chi-squared = 972.63

Degrees of Freedom: df = 3

p-value: < 2.2 x 10⁻¹⁶ (Significant differences among treatments)


Dunn's Post-hoc Test Results - LM02

Comparison	Z-Value	Unadjusted p-value	Adjusted p-value
CTR - DTX	-2.786	5.33×10^{-3}	5.33×10^{-3}
CTR - ED1	+9.169	4.76 x 10 ⁻²⁰	5.72 x 10 ⁻²⁰
DTX - ED1	+15.031	4.57 x 10 ⁻⁵¹	1.37 x 10 ⁻⁵⁰
CTR - ED2	-12.159	5.15 x 10 ⁻³⁴	1.03 x 10 ⁻³³
DTX - ED2	-12.157	5.23 x 10 ⁻³⁴	7.85×10^{-34}
ED1 - ED2	-30.532	9.80 x 10 ⁻²⁰⁵	5.88×10^{-204}

Effect Sizes (Cliff's Delta) - LM02

Comparison	Delta Estimate	Effect Size	95% CI (Lower)	95% CI (Upper)
DTX vs ED2	-0.0984	Negligible	-0.1141	-0.0826
DTX vs ED1	0.1455	Negligible	0.1270	0.1639
DTX vs CTR	0.0303	Negligible	0.0075	0.0531
ED2 vs ED1	0.2374	Small	0.2222	0.2526
ED2 vs CTR	0.1417	Negligible	0.1223	0.1610
ED1 vs CTR	-0.1303	Negligible	-0.1525	-0.1080

LM04



Descriptive Statistics - LM04

Treatment	Sample Size (n)	Mean	SD	Median	IQR
CTR	2128	91.3	51.4	76.9	34.2
DTX	3719	89.8	48.1	75.2	32.3
ED1	6500	93	54.8	78.5	33.5
ED2	2178	85.7	38.9	75.5	28.8

Normality Assessment - LM04

Tests Used: Shapiro-Wilk and Anderson-Darling

Results:

- CTR, DTX, ED2: p-values < 10⁻⁵⁰ (Non-normal distribution)
- ED1: p-value = 3.7×10^{-24} (Non-normal distribution)

Kruksal-Wallis Test Results - LM04

• Test Statistic: Chi-squared = 47

• Degrees of Freedom: df = 3

• p-value: 3 x 10⁻¹⁰ (Significant differences among treatments)

Dunn's Post-hoc Test Results - LM04

Comparison	Z-Value	Unadjusted p-value	Adjusted p-value
CTR - DTX	+1.872	6 x 10 ⁻²	7 x 10 ⁻²
CTR - ED1	-2.200	2 X 10 ⁻²	4 X 10 ⁻²
DTX - ED1	-5.147	2 x 10 ⁻⁷	7 x 10 ⁻⁷
CTR - ED2	+2.971	3 x 10 ⁻³	6 x 10 ⁻³

Effect Sizes (Cliff's Delta) - LM04

Comparison	Delta Estimate	Effect Size	95% CI (Lower)	95% CI (Upper)
ED1 vs ED2	0.0846	Negligible	0.0567	0.1123
ED1 vs DTX	0.0611	Negligible	0.0378	0.0844
ED1 vs CTR	0.0311	Negligible	0.0026	0.0596
ED2 vs DTX	-0.0222	Negligible	-0.0526	0.0082
ED2 vs CTR	-0.0518	Negligible	-0.0861	-0.0173
DTX vs CTR	-0.0287	Negligible	-0.0594	0.0022

Model LM02

Descriptive Statistics:

- Treatment ED2 has the highest mean (93.4) and median (76.2), indicating better performance compared to other treatments.
- CTR has the lowest mean (79.3) and median (71.4), suggesting it performs less effectively.

Normality Assessment:

- All treatments show non-normal distributions based on Shapiro-Wilk and Anderson-Darling tests (p-values < 1.531 x 10⁻⁶¹).
- Kruskal-Wallis Test:
 - Significant differences among treatments (p<2.2 x 10⁻¹⁶).

Dunn's Post-hoc Test:

- Pairwise comparisons reveal significant differences between most treatment groups, particularly:
 - ED1 vs ED2 (p= 5.88×10^{-204}).
 - CTR vs ED1 (p=5.72 x 10⁻²⁰).
- Adjusted p-values confirm statistical significance across comparisons.

Effect Sizes (Cliff's Delta):

- ED2 vs ED1 shows a small effect (=+0.237).
- Negligible effects for the other comparisons.

Model LM04

Descriptive Statistics:

- Treatment ED1 has the highest mean (93) and median (78.5), indicating better performance.
- ED2 has the lowest mean (85.7) and median (75.5), suggesting relatively weaker performance.

Normality Assessment:

 Non-normal distributions for all treatments, confirmed by Shapiro-Wilk and Anderson-Darling tests (p-values < 10⁻⁵⁰).

Kruskal-Wallis Test:

Significant differences among treatments (p=3x10⁻¹⁰).

Dunn's Post-hoc Test:

- Significant pairwise differences observed, especially:
 - DTX vs ED1 (p=7 x 10⁻⁷).
 - CTR vs ED2 (p=6 x 10⁻³).
- Adjusted p-values validate statistical significance for these comparisons.

Effect Sizes (Cliff's Delta):

Negligible effects observed across comparisons

Normal Angiogenesis

Branching Angle Range **20°-45° (Organized)**

Daughter Vessels Length Ratio

0.8 (Longer & Uniform)

Daughter Vessels Radius Ratio

0.7 (Gradual Tapering)

Branching Density

Max Depth = 6 (Moderate)

Carcinogenic Angiogenesis

Branching Angle Range 10°-70° (Chaotic)

Daughter Vessels Length Ratio

0.6 (Shorter & Irregular)

Daughter Vessels Radius Ratio

0.5 (Uneven Tapering)

Branching Density

Max Depth = 9 (Excessive)